Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;104(3):216-220.
doi: 10.1308/rcsann.2021.0154. Epub 2021 Dec 20.

Can one-step nucleic acid amplification assay predict four or more positive axillary lymph node involvement in breast cancer patients: a single-centre retrospective study

Affiliations

Can one-step nucleic acid amplification assay predict four or more positive axillary lymph node involvement in breast cancer patients: a single-centre retrospective study

R Kenny et al. Ann R Coll Surg Engl. 2022 Mar.

Abstract

Background: One-step nucleic acid amplification (OSNA) assay is a proven, accurate, intraoperative method for the detection of lymph node (LN) metastases. The aim of this study was to assess if the total tumour load (TTL) as calculated by OSNA could be used to predict N2 stage disease, ie ≥4 LN containing metastases, in invasive breast cancer patients.

Methods: Between 2011 and 2019 at St Richard's Hospital, Chichester, all macro-metastasis-positive OSNA cases for invasive breast cancer were retrospectively reviewed. The association between clinicopathological variables and ≥4 LNs containing metastases was analysed using regression analysis.

Results: In total, 134 patients with positive sentinel lymph node (SLN) on OSNA undergoing axillary node clearance were analysed, 53% of whom had no further positive LN, 25% had ≥4 lymph nodes positive. TTL was calculated as the aggregate of cytokeratin-19 mRNA copy count of all SLN tissue analysed via OSNA. TTL ≥1.1×105copies/μl and lymphovascular invasion (LVI) were both significant predictors of N2 stage disease on both univariate (TTL p=0.04, LVI p=0.005) and multivariate (TTL p=0.008, LVI p=0.039) regression analysis.

Conclusion: Our findings show that SLN TTL via intraoperative OSNA assay can predict four or more positive axillary LN involvement in invasive breast cancer. This is important in that it may be used intraoperatively by surgeons to decide on whether to proceed with a full axillary node clearance in order to stage the axilla. Further research is required to shape future guidance.

Keywords: Axillary clearance; Breast cancer; OSNA; Sentinel lymph node; Total tumour load.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Receiver operator characteristic curve (AUC) of the total tumour load

References

    1. Lyman GH, Giuliano AE, Somerfield MRet al. . American society of clinical oncology: American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703–7720.10.1200/JCO.2005.08.001 - DOI - PubMed
    1. Pegolo E, Puppin C, Gerometta Aet al. . One-step nucleic acid amplification (OSNA) for intraoperative evaluation of sentinel lymph node status in breast cancer: a comparative study between CK19 protein expression and CK19 mRNA level in primary tumors and lymph node metastasis. Virchows Arch 2013; 463: 7–15.10.1007/s00428-013-1440-2 - DOI - PubMed
    1. Tsujimoto M, Nakabayashi K, Yoshidome Ket al. . One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 2007; 13: 4807–4816.10.1158/1078-0432.CCR-06-2512 - DOI - PubMed
    1. Deambrogio C, Castellano I, Paganotta Aet al. . A new clinical cut-off of cytokeratin 19 mRNA copy number in sentinel lymph node better identifies patients eligible for axillary lymph node dissection in breast cancer. J Clin Pathol 2014; 67: 702–706.10.1136/jclinpath-2014-202384 - DOI - PubMed
    1. Galimberti V, Cole BF, Zurrida Set al. . Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. Lancet Oncol 2013; 14: 297–305.10.1016/S1470-2045(13)70035-4 - DOI - PMC - PubMed